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Background: Despite introduction of effective chemotherapy protocols, it has remained uncertain, if patients with
colorectal cancer (CRC) liver metastases should receive adjuvant therapy. Clinical or molecular predictors may help
to select patients at high risk for disease recurrence and death who obtain a survival advantage by adjuvant
chemotherapy.
Methods: A total of 297 patients with potentially curative resection of CRC liver metastases were analyzed.
These patients had no neoadjuvant therapy, no extrahepatic disease and negative resection margins. The
primary endpoint was overall survival. Patients’ risk status was evaluated using the Memorial Sloan-Kettering
Cancer Center clinical risk score (MSKCC-CRS). Multivariable analyses were performed using Cox proportional
hazard models.
Results: A total of 137 (43%) patients had a MSKCC-CRS > 2. Adjuvant chemotherapy was administered to 116
(37%) patients. Patients who received adjuvant chemotherapy were of younger age (p = 0.03) with no significant
difference in the presence of multiple metastases (p = 0.72) or bilobar metastases (p = 0.08). On multivariate
analysis adjuvant chemotherapy was associated with improved survival in the entire cohort (Hazard ratio 0.69; 95%
confidence interval 0.69–0.98). It improved survival markedly in high-risk patients with a MSKCC-CRS > 2 (HR 0.40; 95% CI
0.23–0.69), whereas it was of no benefit in patients with a MSKCC-CRS ≤ 2 (HR 0.90; 95% CI 0.57–1.43).
Conclusions: The MSKCC-CRS offers a tool to select patients for adjuvant therapy after resection of CRC liver metastases.
Validation in independent patient cohorts is required.
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The liver represents the most frequent metastatic site in
patients with colorectal cancer (CRC). At the time of
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reproduction in any medium, provided the orpatients will develop metastatic disease to the liver after
radical resection of the colorectal primary [1]. At present,
complete surgical resection is the primary therapy for pa-
tients with CRC liver metastases and in selected cases may
enable 5-year survival rates of 30–50% [2,3].
Studies on the treatment of primary CRC have fueled
discussions, if adjuvant chemotherapy improves survival
after resection of CRC liver metastases [4-6]. The avail-
able randomized controlled trials did not evaluate
modern chemotherapy protocols and, moreover, lack
sufficient power to draw final conclusions [7]. The
EORTC Intergroup Trial 40983 showed a significantLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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who received pre-and postoperative therapy with the
FOLFOX-4 protocol compared to surgery alone [8].
Disadvantages of neoadjuvant therapy such as in-
creased perioperative morbidity, parenchymal injury
and reduced treatment options in case of disease
recurrence need to be considered and possibly out-
weigh the observed benefit in progression-free sur-
vival. The long-term results of the EORTC Intergroup
Trial 40983 indeed did not show a significant improve-
ment in five-year overall survival in the perioperative
chemotherapy group [9]. The available clinical data
therefore clearly demonstrate the need for strategies to
tailor adjuvant therapy to patients who are likely to
obtain a marked therapy-induced benefit in long-term
outcome after potentially curative resection of CRC
liver metastases.
It was therefore the aim of the present study to evaluate,
if patients’ clinical risk profile using the Memorial Sloan-
Kettering Cancer Center clinical risk score (MSKCC-CRS)
may serve as a tool to predict the efficacy of adjuvant
chemotherapy after resection of colorectal liver metastases
[2]. This clinical score consists of five criteria (node-positive
primary, disease-free interval < 12 months, >1 tumor, tumor
size > 5 cm, CEA >200 ng/ml) and has repeatedly shown
adequate prognostic stratification of patients undergoing
resection for CRC liver metastases [3,10-12].Patients and methods
Study population
Patients were identified from a prospective database
maintained at the Department of General, Visceral
and Transplantation Surgery, University of Heidelberg.
CRC patients who underwent surgical resection for
histologically proven liver metastases between October
2001 and June 2009 and received adjuvant chemother-
apy or no adjuvant therapy after potentially curative
resection were eligible for the analyses. We excluded
patients who had received neoadjuvant therapy prior
to hepatic resection, patients who already had previous
resection of CRC metastases, patients with extrahe-
patic disease and those with positive resection margins.
Furthermore, patients who received targeted therapy in
the adjuvant setting were excluded. Potentially curative
surgery was defined as complete resection of all liver
metastases, regardless of size, number, distribution, or
width of (negative) resection margin and might have
been completed by concomitant local ablation of small
lesions (< 3 cm in diameter). Tumor stage was classi-
fied according to the seventh edition of the TNM clas-
sification of the UICC (International Union Against
Cancer) [13]. The study was approved by the independ-
ent ethics committee of the University of Heidelberg.Patient treatment and follow-up
Patients were treated as described previously [3,14-16].
Preoperative work-up included a physical examination,
serum CEA levels and a computed tomography (CT)
scan of the abdomen and chest. Furthermore, a colonos-
copy and pelvic magnetic resonance imaging (MRI) was
required in patients with colon and rectal primaries, re-
spectively. Patients with significant medical comorbidities
were referred for an extensive cardiopulmonary evaluation.
Intraoperative ultrasound of the liver was performed in all
patients. Liver resection was carried out under low central
venous pressure using a the clamp-crushing technique,
ultrasonic dissector or stapler transection [17]. Hepatic in-
flow control (i.e. portal triad clamping) was not used regu-
larly [18]. After hepatic resection follow-up visits were
performed at regular intervals at the outpatient clinics of
the Department of Surgery, University of Heidelberg and
the National Center for Tumor Diseases (NCT) Heidelberg.
Patients were followed with serum CEA measurement, ab-
dominal ultrasound and chest X-ray every three months for
the first two years and every six months thereafter. A CT of
the chest and abdomen was performed initially after three
months and then every six months for two years. In the ab-
sence of recurrent disease CT scans were performed annu-
ally thereafter.
The decision for adjuvant therapy as well as the chemo-
therapy protocol was made within a multidisciplinary set-
ting. While the decision for adjuvant chemotherapy was
made on an individual basis for each patient, the following
factors were taking into account: clinicopathologic factors
(i.e. disease-free interval, extent of disease, organ function,
recovery from surgery, etc.), extent and tolerance of chemo-
therapy pretreatment and patients’ preference.
Adjuvant chemotherapy was initiated within 4 to
6 weeks after surgery. Most of the patients selected for a
5-FU/LV-regimen were treated with LV at 500 mg/m2 IV
over 2 h plus a 24-hour continuous 5-FU infusion at
2600 mg/m2 on day 1, 8, 15, 22, 29, 36, repeated on day
50, for 3 cycles [19]. In a few patients, alternative weekly
infusional 5-FU/LV-regimens were applied. Patients se-
lected for an oxaliplatin-based regimen received FOL-
FOX4 (oxaliplatin at 85 mg/m2 IV over 2 h on day 1,
plus leucovorin (LV) at 200 mg/m2 IV over 2 h on day 1
and 2, plus 5-fluorouracil (5-FU) at 400 mg/m2 IV bolus
on day 1 and 2, plus a 22-hour continuous 5-FU infusion
at 600 mg/m2 for 2 consecutive days, every two weeks
[20]. The FOLFIRI regimen was administrated as follow-
ing: Irinotecan at 180 mg/m2 IV over 1 h on day 1, plus
LV at 400 mg/m2 IV over 2 h on day 1, plus 5-FU at
400 mg/m2 IV bolus on day 1, plus a 46-hour continu-
ous 5-FU infusion at 2400 mg/m2, every two weeks [21].
Alternative FOLFOX or FOLFIRI regimens were applied
in selected patients who received adjuvant therapy at ex-
ternal institutions.
Table 1 Clinicopathologic characteristics of patients who
underwent potentially curative resection for colorectal
cancer liver metastases
n (%) or median (range)
n 297 (100)
Gender
Male 199 (67)
Female 98 (33)
Age [years] 64 (30 – 88)
Initial stage of disease [UICC]
I 22 (7)
II 56 (19)
III 94 (32)
IV 125 (42)
Site of primary tumor
Colon 166 (56)
Rectum 131 (44)
CEA level [μg/l]1 15.1 (0.5 – 7606)
Time of metastasis
Synchronous 125 (42)
Metachronous 172 (58)
Number of metastases
1 160 (54)
> 1 137 (46)
Size of largest metastasis
< 5 cm 143 (48)
≥ 5 cm 154 (52)
Distribution of metastases
Unilobar 186 (63)
Bilobar 111 (37)
Extent of liver resection
Major resection (>2 segments) 172 (58%)
Minor resection (≤2 segments) 125 (42%)
MSKCC clinical risk score
≤ 2 171 (58)
> 2 126 (42)
1Prior to resection of colorectal cancer liver metastases.
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Patients’ risk status was evaluated preoperatively using
the MSKCC-CRS [2], as its prognostic value has been
confirmed in multiple analyses from various institu-
tions [3,10,11]. This score uses the following five prog-
nostic parameters: size of the largest metastasis > 5 cm,
node-positive primary tumor, multiple metastases,
preoperative CEA level > 200 ng/ml and disease-free
interval from the primary to the diagnosis of liver me-
tastasis < 12 months. Based on the number of criteria
met patients are classified into six different risk groups
(MSKCC-CRS 0–5).
Statistical analyses
Continuous data were reported as median (range) and
categorical data were expressed as absolute and relative
frequencies. Continuous and categorical data were com-
pared with Student’s t-test, Wilcoxon test and Pearson’s
χ2-test, respectively. The primary endpoint was overall
survival. Patients who were lost to follow-up were cen-
sored at the date of last contact, as were patients who
were alive at the time of the last follow-up visit. Cox
proportional hazards regression models were used for
multivariate analyses and included known prognostica-
tors in patients with colorectal liver metastases. All p
values were two-sided. A p-value < 0.05 was considered
to indicate statistical significance. All analyses were done
using SPSS® software version 17 (SPSS, Chicago, Illinois,
USA) and JMP program version 7 (SAS Institute Inc.,
Cary, NC, USA).
Results
A total of 386 patients who underwent resection of colo-
rectal liver metastases during the study period of eight
years were identified from the database. After exclusion of
patients who had received neoadjuvant therapy, patients
with recurrent liver metastases or extrahepatic disease and
those with positive resection margins a total of 297 pa-
tients with a potentially curative resection of CRC liver
metastases remained eligible for final analyses (Table 1).
There were 199 (67%) men and 98 (33%) women with a
median age of 64 (30–88) years. Of these, 125 (42%) pa-
tients had synchronous metastases. The primary tumor
was located in the colon and in the rectum in 166 (56%)
and 131 (44%) patients, respectively. There were 137
(46%) patients with multiple metastases and 110 (37%) pa-
tients with a bilobar distribution of metastatic lesions. A
major resection (i.e. resection of > 2 anatomic segments)
was carried out in 172 (58%) patients and was performed
similarly in patients with a MSKCC-CRS ≤2 (n = 85; 50%)
and MSKCC-CRS > 2 (n = 87; 69%). Some 87 (92.5%) pa-
tients with stage III disease and 7 (12.5%) patients with
stage II disease had received adjuvant chemotherapy after
resection of the primary tumor.Fifteen patients received local ablation. In the group of
patients with MSKCC-CRS ≤2 three patients with and
four patients without adjuvant therapy had local abla-
tions. In the group of patients with a MSKCC-CRS > 2
three patients with and five patients without adjuvant
therapy had local ablations. A total of 46 (39.6%) pa-
tients with adjuvant chemotherapy after liver resection
for colorectal metastases had not received any adjuvant
chemotherapy after resection of the primary tumor.
However, 54 (29.8%) patients who had no adjuvant
chemotherapy after resection of liver metastases, had
Table 2 Clinicopathologic characteristics of patients who
underwent resection for colorectal cancer liver metastases
stratified for the administration of adjuvant therapy
No adjuvant
CTx
Adjuvant
CTx
P
value
n 181 (61) 116 (39)
Gender 0.11
Male 115 (64) 84 (72)
Female 66 (36) 32 (28)
Age [years] 64 (30 – 88) 63 (33 – 83) 0.03
Initial stage of disease
(UICC)
0.53
I 23 (7) 9 (8)
II 37 (21) 17 (15)
III 56 (32) 36 (31)
IV 70 (40) 53 (46)
Site of primary tumor 0.14
Colon 95 (52) 71 (61)
Rectum 86 (47) 45 (39)
CEA level [μg/l) 12.6 (0.6 – 2032) 18.1
(0.5 – 7606)
0.63
Number of metastases 0.72
1 99 (55) 61 (53)
> 1 82 (45) 55 (47)
Size of largest metastasis 0.06
< 5 cm 95 (52) 48 (41)
≥ 5 cm 86 (48) 68 (59)
Distribution of metastases 0.08
Unilobar 120 (67) 66 (57)
Bilobar 60 (33) 55 (43)
MSKCC clinical risk score 0.07
≤ 2 111 (61) 60 (52)
> 2 69 (39) 56 (48)
Data are presented as n (%) or median (range). CTx, Chemotherapy.
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primary tumor. In 25 (8.3%) patients the information
on adjuvant chemotherapy was missing. A total of 125
(42%) patients had a MSKCC-CRS > 2. The distribution
of patients across the MSKCC-CRS 0 to 5 was 14 (5%),
51 (17%), 106 (36%), 76 (26%), 43 (14%) and 6 (2%)
patients. With respect to the further criteria of the
MSKCC-CRS 26 (8.7%) patients had a preoperative CEA
level > 200 ng/ml, 197 (65.9%) patients a node-positive
primary tumor and 178 (59.5%) patients a time interval
< 12 months from the diagnosis of CRC to the diagnosis
of metastatic disease to the liver.
More than half of the patient cohort did not receive
adjuvant therapy (n = 181; 61%) and some 116 (39%)
patients were treated with cytotoxic chemotherapy. The
median time to the start of adjuvant chemotherapy was
6 weeks (range: 4–8 weeks). The kind of adjuvant chemo-
therapy was FOLFOX in 62 (53%) patients, FOLFIRI in 16
(14%) patients and 5-FU/Leucovorin in 38 (33%) patients.
Patients with a MSKCC-CRS ≤ 2 (n = 111; 62%) were more
likely to receive no adjuvant chemotherapy compared to
patients with a score > 2 (n = 70; 38%). Administration of
5-FU/Leucovorin was rather balanced between patients
with and without a high MSKCC-CRS, whereas patients
with a high MSKCC-CRS more frequently received FOL-
FIRI (Additional file 1: Table S1). The median duration of
chemotherapy was 3 months (range: 1.5–6 months). In 9
patients chemotherapy was stopped due to toxicity.
Table 2 presents patients’ clinicopathologic characteristics
stratified for the administration of adjuvant therapy. We
noticed a significant difference between the two groups re-
garding patients’ age (p = 0.03). Variables describing the ex-
tent of metastatic disease to the liver such as the presence
of multiple metastases (p = 0.72), size of metastases ≥ 5 cm
(p = 0.06) and presence of bilobar disease (p = 0.08) did not
differ significantly among the groups.
After the date of primary hepatic resection for metastatic
disease patients were followed for a median duration of
32 months (3–107 months). A total of 153 (52%) patients
died during the follow-up period. Six (2%) patients who
were lost to follow-up were censored at the date of last
contact.
To evaluate the independent clinical value of adjuvant
chemotherapy a multivariate model was built including
the kind of adjuvant therapy together with the initial
stage of disease, presence of bilobar metastases and the
MSKCC-CRS as known prognostic factor in our patient
cohort (Table 3). This analysis demonstrated an advantage
in overall survival for patients who received adjuvant
chemotherapy (Hazard ratio 0.69; 95% confidence interval
0.49–0.98; p = 0.04). Moreover, this multivariate model con-
firmed a prognostic impact of bilobar metastases (HR 1.68;
95% CI 1.18–2.39; p = 0.004) and a MSKCC-CRS > 2 (HR
1.56; 95% CI 1.04–2.33; p = 0.02).Owing to the known prognostic value of the MSKCC-
CRS in our patients as well as other patient cohorts
[3,10,11], we stratified the multivariate model for a
MSKCC-CRS of ≤ 2 and > 2 to further evaluate a poten-
tial benefit of adjuvant chemotherapy in low and high-
risk patients, respectively (Table 4). The multivariate
analysis of patients with a MSKCC-CRS ≤ 2 revealed
no survival benefit of adjuvant chemotherapy (HR
0.90; 95% CI 0.57–1.43; p = 0.67). However, there was a
strong advantage in overall survival for patients who
received adjuvant chemotherapy in the multivariate
model restricted to patients with a MSKCC-CRS > 2
(HR 0.40; 95% CI 0.23–0.70; p = 0.001) (Figure 1).
We performed subgroup analyses to further elucidate
the efficacy of adjuvant chemotherapy in patients with a
Table 3 Multivariate analysis of factors associated with overall survival in patients who underwent potentially curative
resection for colorectal cancer liver metastases
Variable Comparison Hazard ratio 95% CI P Value
Age - 1.01 0.99 – 1.03 0.20
Distribution of metastasis Bilobar vs. unilobar 1.68 1.18 – 2.39 0.004
MSKCC Clinical risk score 3-5 vs. 0-2 1.56 1.04 – 2.33 0.02
Initial stage of disease (UICC) 0.29
Reference
2 1.68 0.73 – 3.87 0.21
3 1.88 0.85 – 4.18 0.11
4 1.44 0.63 – 3.25 0.38
Adjuvant chemotherapy Adjuvant CTx vs. no adjuvant CTx 0.69 0.49 – 0.98 0.04
CTx, Chemotherapy.
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applied cut-off for the MSKCC-CRS (≤ 2 vs. > 2) to
stratify patients in a low-and high-risk group. These
analyses revealed that adjuvant chemotherapy failed to
improve survival in patients with a MSKCC-CRS of 2,
whereas it was associated with a significant survival
benefit in patients with a MSKCC-CRS of 3 (Figure 2).
Discussion
There is limited evidence on the efficacy of adjuvant
therapy to prolong survival after potentially curative
resection of CRC liver metastases. The available randomizedTable 4 Multivariate analysis of factors associated with overa
resection for colorectal cancer liver metastases stratified for p
Variable Comparison
MSKCC clinical risk score ≤ 2
Age -
Distribution of metastasis Bilobar vs. unilobar
Initial stage of disease (UICC)
1
2
3
4
Adjuvant chemotherapy Adjuvant CTx vs. no adjuvant CT
MSKCC clinical risk score > 2
Age -
Distribution of metastasis Bilobar vs. unilobar
Initial stage of disease (UICC)
1
2
3
4
Adjuvant chemotherapy Adjuvant CTx vs. no adjuvant CT
CTx, Chemotherapy.controlled trials were not placebo-controlled and lacked
sufficient statistical power to detect differences in sur-
vival [22-25]. Mitry et al. published a pooled analysis of
two randomized trials that evaluated adjuvant therapy
with bolus 5-FU/LV on a combined population of 302
patients [7]. In this study the benefit of adjuvant therapy
for progression-free survival and overall survival failed
to reach statistical significance. However, multivariate
analyses adjusting for the number of metastases, prior
chemotherapy (analysis of progression-free survival) and
the disease-free interval (analysis of overall survival) favored
adjuvant chemotherapy with regard to progression-freell survival in patients who underwent potentially curative
atients’ MSKCC clinical risk score
Hazard ratio 95% CI P Value
1.01 0.99 – 1.04 0.20
1.80 1.12 – 2.92 0.01
0.41
Reference
1.96 0.80 – 4.81 0.13
1.92 0.80 – 4.59 0.14
1.52 0.60 – 3.83 0.36
x 0.90 0.57 – 1.43 0.67
1.00 0.98 – 1.03 0.61
1.65 0.98 – 2.77 0.06
0.21
Reference
0.21 0.02 – 2.27 0.20
0.60 0.07 – 4.79 0.63
0.38 0.05 – 3.03 0.36
x 0.40 0.23 – 0.70 0.001
Figure 1 Influence of adjuvant chemotherapy on overall survival after potentially curative resection of colorectal liver metastases depending
on patients’ risk status. A. Overall survival of patients with a MSKCC-CRS≤ 2 stratified for the type of adjuvant therapy (p = 0.53). B. Overall survival of
patients with a MSKCC-CRS > 2 stratified for the type of adjuvant therapy (p = 0.007). Data are presented as Cox proportional hazards.
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Figure 2 Influence of adjuvant chemotherapy on overall survival after potentially curative resection of colorectal liver metastases in patients
with a borderline risk status. A. Overall survival of patients with a MSKCC-CRS 2 stratified for the type of adjuvant therapy (p = 0.62). B. Overall survival of
patients with a MSKCC-CRS 3 stratified for the type of adjuvant therapy (p = 0.01). Data are presented as Cox proportional hazards.
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http://www.biomedcentral.com/1471-2407/14/174survival (HR 1.39; 95% CI 1.04–1.85) and overall survival
(HR 1.39; 95% CI 1.00–1.93).
The benefit in overall survival reported by Mitry et al.
for patients who received adjuvant therapy is very similar to
the risk reduction observed in our study. While these au-
thors did not evaluate the outcome after adjuvant therapy
depending on patients’ preoperative risk status, the lack of
a clear survival benefit with adjuvant chemotherapy may in
part also be caused by the use of less active protocols.
Chemotherapy with 5-FU/LV has been the standard adju-
vant chemotherapy for patients with colorectal liver metas-
tases. Various studies on systemic therapy of metastatic
CRC have demonstrated improved efficacy of chemother-
apy protocols including oxaliplatin [26-28] or irinotecan
[29-31] to 5-FU/LV. Together with studies that proved sig-
nificantly better long-term outcome of patients receiving
modern combination chemotherapy for adjuvant treatment
after resection of the colorectal primary [20,32] these data
raised the question, of efficacy of adjuvant chemotherapy
after resection of colorectal liver metastases can be further
improved by addition of oxaliplatin or irinotecan to 5-FU/
LV. In a recently published phase III trial Ychou et al. evalu-
ated adjuvant therapy after surgery for colorectal liver
metastases using the 5-FU/LV backbone with or without
irinotecan [33]. This study included 306 patients and failed
to demonstrate a significant advantage in disease-free sur-
vival for patients who received adjuvant FOLFIRI.
The lack of stratified analyses considering patients’ risk
status might serve as a further explanation, why the
available studies failed to demonstrate a clear survival
benefit for patients treated with adjuvant chemotherapy.
Using the MSKCC-CRS that has been validated in sev-
eral studies [3,10,11], we here show that adjuvant ther-
apy is highly active in high-risk patients, whereas it is
not associated with prolonged survival in patients with
low-risk disease features. Our results confirm the find-
ings by Parks et. who reported the long-term outcomes
after adjuvant therapy in a cohort of 792 patients with
hepatic resection at two institutions between 1991 and
1998 [34]. Although these authors showed a survival
benefit of adjuvant chemotherapy in particular for pa-
tients with a MSKCC-CRS of 4 and 5, one should note
that in this analysis 5-FU based chemotherapy was ad-
ministered only, without addition of oxaliplatin, irinote-
can. Further evidence supporting the use of adjuvant
therapy primarily in high-risk patients is provided by
a recent multi-institutional study on 1471 patients who
underwent resection for solitary, metachronous and pri-
marily resectable metastases without extrahepatic disease
[35]. In this study of patients with potentially curative
resection modern chemotherapy protocols were ap-
plied. The authors reported a benefit of adjuvant
chemotherapy in patients with a metastasis > 5 cm or
more in diameter, whereas there was no influence ofadjuvant chemotherapy in patients with tumors less a
size than 5 cm. Together with the results of our study
these data suggest that allocation in future randomized
controlled trials should be stratified for patients’ risk
status to identify those patients who benefit from adju-
vant chemotherapy. The ideal tool to evaluate patients’
risk status, however, remains to be determined. Al-
though the present study favors the MSKCC-CRS,
there is evidence that the predictive value of this scor-
ing system may be further improved by additional/al-
ternative molecular or clinical markers [36]. Additional
studies are required to determine the benefit of adju-
vant chemotherapy based on the results of various risk
assessment tools in order to identify the most accurate
classification system.
The finding that adjuvant chemotherapy improves sur-
vival exclusively in patients with high-risk clinical fea-
tures of disease supports efforts to identify prognostic
biomarkers indicating patients with a high-likelihood of
tumor relapse and cancer-related death. Numerous stud-
ies have so far investigated various cellular, molecular or
genetic markers as predictors of outcome in patients
with primary and metastatic CRC [37-39]. The inconsist-
ent findings of most studies, which may be explained by
insufficient statistical power, differences in the experi-
mental setup and patient cohorts have prevented the
widespread use of predictive markers in patients with
primary and metastatic CRC. One should, however, note
that there are far less data on predictors of poor long-
term outcome for patients undergoing potentially cura-
tive resection of colorectal liver metastases. There is
evidence that expression of certain markers within resected
liver metastases may predict disease recurrence and sur-
vival [40-42]. In a recently published analyses on 107 pa-
tients who underwent potentially curative resection for
colorectal liver metastases we demonstrated that preopera-
tive level of circulating placental growth factor was
associated independently with the risk of disease recur-
rence [43]. While these results need to be validated in
independent patient populations, further studies are
required to determine the optimal timing for the as-
sessment of circulating biomarkers as predictors of
outcome after resection of CRC liver metastases [44].
These data should present the basis for the conduction
of prospective clinical trials evaluating the efficacy of
adjuvant chemotherapy depending on patients’ angio-
genic profile.
Conclusion
In conclusion, the present study shows that adjuvant
chemotherapy after potentially curative resection of CRC
liver metastases is associated with favorable outcome in
high-risk patients, whereas it offers no survival benefit in
patients with low-risk features of disease. The MSKCC-
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resection of CRC liver metastases. Although validation of
these results is required in independent patient cohorts, the
present data strongly suggest that patients in studies on
adjuvant chemotherapy after potentially curative resection
of colorectal liver metastases should be stratified for their
risk status.
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